Tumor-derived biomarkers beyond antigen expression enhance efficacy of CD276/B7H3 antibody-drug conjugate in metastatic prostate cancer
S. Agarwal, L. Fang, K. McGowen, J. Yin, J. Bowman, A. N. Alilin, A. T. Ku, E. Corey, M. Roudier, L. True, R. Dumpit, I. Coleman, J. Lee, P. S. Nelson, B. J. Capaldo, , K. Kelly
This study identifies biomarkers beyond B7H3 expression that predict response to a B7H3-ADC in metastatic prostate cancer models, improving therapeutic efficacy.
bioRxiv · Apr 19, 2022 · PreprintCancer Biology